Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

curium belgium s.p.r.l.-b.v.b.a. - pentetreotide 20,8 mg - kit for radiopharmaceutical preparation - 20,8 mg - calcium trisodium diethylenetriaminepentaacetate (dtpa) 20.8 mg - technetium (99mtc) pentetic acid

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

narodowe centrum badan jadrowych pl - hynic-[d-phe1,tyr3-octreotide] trifluoroacetate 20 µg - kit for radiopharmaceutical preparation - 20 µg - hynic-[d-phe1,tyr3-octreotide] trifluoroacetate 20 µg - technetium (99mtc) hynic-octreotide

Kanada - angličtina - Health Canada

baxter corporation - sodium chloride - solution - 20% - sodium chloride 20% - replacement preparations

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - soya oil 20%{relative};  ;   - solution for infusion - 20 % - active: soya oil 20%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ethinylestradiol 20ug; levonorgestrel 100ug - coated tablet - 20µg/100µg - active: ethinylestradiol 20ug levonorgestrel 100ug excipient: calcium carbonate glycerol glycol montanate iron oxide red iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc purified water starch sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - oral contraception

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

leo pharma limited - azelaic acid 20% - topical cream - 20 % - active: azelaic acid 20% excipient: benzoic acid cetearyl octanoate glycerol cutina cbs polyethylene glycol 200 monostearate propylene glycol purified water - topical treatment of acne vulgaris.

Singapur - angličtina - HSA (Health Sciences Authority)

blood services group, health sciences authority - human albumin - injection, solution, concentrate - 20.00% - human albumin 20%

Singapur - angličtina - HSA (Health Sciences Authority)

euro asia medico pte. ltd. - albumin (human) - injection - 20% w/v - albumin (human) 20% w/v

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; magnesium stearate; light magnesium oxide; crospovidone; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - pharmacor rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events pharmacor rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). pharmacor rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia pharmacor rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with pharmacor rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; microcrystalline cellulose; crospovidone; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - pharmacor rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events pharmacor rosuvastatin is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). pharmacor rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia pharmacor rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with pharmacor rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.